
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics is a promising biopharmaceutical company with a strong focus on developing circuit-specific treatments for central nervous system disorders. The positive results from their Phase 2 IRIS trial and potential sales of $1.5B for their schizophrenia and AD psychosis drug bode well for their future success. With a dedicated team of leaders in psychiatry and neuroscience and a pipeline of potential treatments, MapLight has the potential to make a significant impact in the neuropsychiatry market. However, they will have to navigate potential risks and competition in order to fully capitalize on their innovations.
Bears say
MapLight Therapeutics is heavily reliant on the success of their drug candidate, ML-007C-MA, as their only source of potential revenue. Any delays or setbacks in the clinical trials could significantly impact the company's financials. With data not expected until 2026 and 2027, it will be a few more years before the company can show any tangible results or gain FDA approval. The market for CNS disorders is highly competitive and the company's financials do not currently reflect a strong position in the market, making it a high-risk investment.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares